Jarle Jortveit1, Ragna Elise Støre Govatsmark2, Tormod Aarlott Digre2, Cecilie Risøe3, Torstein Hole4, Jan Mannsverk5, Stig Arild Slørdahl6, Sigrun Halvorsen7. 1. Kardiologisk avdeling Hjerteseksjonen Medisinsk avdeling Sørlandet sykehus Arendal. 2. Kardiologisk avdeling Norsk hjerteinfarktregister St. Olavs hospital. 3. Kardiologisk avdeling Oslo universitetssykehus, Rikshospitalet. 4. Hjertemedisinsk avdeling Klinikk for medisin Helse Møre og Romsdal. 5. Hjertemedisinsk avdeling Universitetssykehuset Nord-Norge. 6. Hjertemedisinsk avdeling St. Olavs hospital og Norges teknisk-naturvitenskapelige universitet. 7. Hjertemedisinsk avdeling Oslo universitetssykehus, Ullevål.
Abstract
BACKGROUND: The Norwegian Myocardial Infarction Registry was established in 2012 as a national quality registry. This first report from the registry presents the number of myocardial infarctions, the treatment provided and the 30-day mortality rate for myocardial infarctions admitted to Norwegian hospitals. MATERIAL AND METHOD: All patients with myocardial infarction admitted to Norwegian hospitals in 2013 and recorded in the Norwegian Myocardial Infarction Registry are included. The number of myocardial infarctions, patient characteristics and their treatment are indicated for myocardial infarctions with and without ST-segment elevation on ECG (STEMI and nSTEMI). The 30-day mortality is calculated for each health region. RESULTS: In 2013, a total of 13,043 myocardial infarctions in 12,336 patients were recorded in the Norwegian Myocardial Infarction Registry. Altogether 3,658 (28%) of the infarctions were classified as STEMI and 9,188 (70%) as nSTEMI. The average age at the time of the infarction was 68.1 years for men and 75.9 years for women. Percutaneous coronary intervention was performed for a total of 2,798 (77%) ST-segment elevation myocardial infarctions, whereas the corresponding number for nSTEMI was 3,179 (35%). The 30-day mortality in the entire infarction population was 10% (< 60 years: 2%, 60-69 years: 4%, 70-79 years: 9%, ≥ 80 years: 20%). We found no differences in mortality between health regions or between men and women. INTERPRETATION: This first report from the Norwegian Myocardial Infarction Registry shows that the treatment service is functioning well for most patients. Secondary prophylaxis using drug therapy and increased use of invasive examination of patients with nSTEMI appear to be areas for improvement.
BACKGROUND: The Norwegian Myocardial Infarction Registry was established in 2012 as a national quality registry. This first report from the registry presents the number of myocardial infarctions, the treatment provided and the 30-day mortality rate for myocardial infarctions admitted to Norwegian hospitals. MATERIAL AND METHOD: All patients with myocardial infarction admitted to Norwegian hospitals in 2013 and recorded in the Norwegian Myocardial Infarction Registry are included. The number of myocardial infarctions, patient characteristics and their treatment are indicated for myocardial infarctions with and without ST-segment elevation on ECG (STEMI and nSTEMI). The 30-day mortality is calculated for each health region. RESULTS: In 2013, a total of 13,043 myocardial infarctions in 12,336 patients were recorded in the Norwegian Myocardial Infarction Registry. Altogether 3,658 (28%) of the infarctions were classified as STEMI and 9,188 (70%) as nSTEMI. The average age at the time of the infarction was 68.1 years for men and 75.9 years for women. Percutaneous coronary intervention was performed for a total of 2,798 (77%) ST-segment elevation myocardial infarctions, whereas the corresponding number for nSTEMI was 3,179 (35%). The 30-day mortality in the entire infarction population was 10% (< 60 years: 2%, 60-69 years: 4%, 70-79 years: 9%, ≥ 80 years: 20%). We found no differences in mortality between health regions or between men and women. INTERPRETATION: This first report from the Norwegian Myocardial Infarction Registry shows that the treatment service is functioning well for most patients. Secondary prophylaxis using drug therapy and increased use of invasive examination of patients with nSTEMI appear to be areas for improvement.
Authors: Anders Green; Anton Pottegård; Anne Broe; Thomas Goldin Diness; Martha Emneus; Pål Hasvold; Gunnar H Gislason Journal: BMJ Open Date: 2016-05-12 Impact factor: 2.692
Authors: Henrik Wåhlberg; Per Christian Valle; Siri Malm; Øistein Hovde; Ann Ragnhild Broderstad Journal: BMC Health Serv Res Date: 2017-03-07 Impact factor: 2.655
Authors: Ingo Ahrens; Oleg Averkov; Eduardo C Zúñiga; Alan Y Y Fong; Khalid F Alhabib; Sigrun Halvorsen; Muhamad A B S K Abdul Kader; Ricardo Sanz-Ruiz; Robert Welsh; Hongbin Yan; Philip Aylward Journal: Clin Cardiol Date: 2019-07-17 Impact factor: 2.882
Authors: Laila A Hopstock; Anne Elise Eggen; Maja-Lisa Løchen; Ellisiv B Mathiesen; Amalie Nilsen; Inger Njølstad; Tom Wilsgaard Journal: Open Heart Date: 2018-01-03